01167.HK
Jacobio Pharmaceuticals Group Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 6.44
+1.90%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 929.9M | 52.1M | 155.7M | 63.5M | 95.7M |
| Cost of Revenue | 66.9M | 22.8M | 28.7M | 60.3M | 83.1M |
| Gross Profit | 889.1M | 29.3M | 155.7M | 3.2M | 12.6M |
| Operating Expenses | |||||
| R&D Expense | 413.0M | 165.5M | 330.2M | 372.3M | 445.6M |
| SG&A Expense | 70.3M | 8.4M | 43.1M | 46.6M | 42.6M |
| General & Admin Expense | 40.4M | 8.4M | 43.1M | 46.6M | 42.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (16.3M) | 21.1M | (29.3M) | (17.9M) | (830.0K) |
| Total Operating Expenses | 467.0M | 195.0M | 343.9M | 401.1M | 487.4M |
| Cost and Expenses | 507.8M | 217.8M | 343.9M | 461.4M | 489.9M |
| Operating Income (EBIT) | 422.0M | (165.7M) | (188.2M) | (397.9M) | (394.2M) |
| Non-Operating | |||||
| Interest Income | 56.9M | 30.9M | 40.9M | 47.1M | 24.6M |
| Interest Expense | 10.8M | 12.6M | 8.4M | 8.3M | 2.3M |
| Net Interest Income | 46.0M | 18.3M | 32.5M | 38.8M | 22.3M |
| Other Non-Op Income/Expense | 39.1M | 23.5M | 32.5M | 38.8M | 22.3M |
| Non-Operating Income (excl Interest) | 6.9M | — | 15.0M | (47.1M) | 86.7M |
| EBT (Pre-Tax Income) | 461.2M | (142.2M) | (155.7M) | (359.1M) | (371.9M) |
| Income Tax Expense | (24.7K) | — | — | — | — |
| Bottom Line | |||||
| Net Income | 461.1M | (142.2M) | (155.7M) | (359.1M) | (371.9M) |
| Earnings from Cont. Ops | 461.2M | (142.2M) | (155.7M) | (359.1M) | (371.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 461.1M | (142.2M) | (155.7M) | (359.1M) | (371.9M) |
| Per Share | |||||
| Basic EPS | HK$0.59 | (HK$0.18) | (HK$0.20) | (HK$0.46) | (HK$0.49) |
| Diluted EPS | HK$0.59 | (HK$0.18) | (HK$0.20) | (HK$0.46) | (HK$0.50) |
| Revenue Per Share | HK$1.19 | HK$0.07 | HK$0.20 | HK$0.08 | HK$0.13 |
| Shares | |||||
| Basic Shares Outstanding | 778.9M | 774.5M | 774.8M | 772.8M | 751.9M |
| Diluted Shares Outstanding | 778.9M | 774.5M | 774.8M | 772.8M | 751.9M |
| Profitability Metrics | |||||
| EBITDA | 457.4M | (143.5M) | (192.4M) | (325.7M) | (355.8M) |
| D&A | 42.3M | 22.2M | 10.8M | 25.1M | 13.8M |
| EBIT | 415.1M | (165.7M) | (203.2M) | (350.8M) | (369.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026